Intravitreal Gene Therapy for Wet AMD

Patients Receiving Autologous Stem Cell Transplant After Chemical Burns Show Corneal Improvements

Optic Atrophy Gene Therapy Cleared for Trials in Australia

Around the Helix: Cell and Gene Therapy Company Updates – September 20, 2023

Ocugen’s Gene-Agnostic Gene Therapy OCU400 Demonstrates Improvement or Stabilization in Retinitis Pigmentosa, Leber Congenital Amaurosis

First Patient Dosed With LCA5 Gene Therapy

Around the Helix: Cell and Gene Therapy Company Updates – September 27, 2023

Patients Receiving Autologous Stem Cell Transplant After Chemical Burns Show Corneal Improvements

Optic Atrophy Gene Therapy Cleared for Trials in Australia

Around the Helix: Cell and Gene Therapy Company Updates – September 20, 2023

Ocugen’s Gene-Agnostic Gene Therapy OCU400 Demonstrates Improvement or Stabilization in Retinitis Pigmentosa, Leber Congenital Amaurosis

First Patient Dosed With LCA5 Gene Therapy

Around the Helix: Cell and Gene Therapy Company Updates – September 27, 2023

Patients Receiving Autologous Stem Cell Transplant After Chemical Burns Show Corneal Improvements

Optic Atrophy Gene Therapy Cleared for Trials in Australia

Around the Helix: Cell and Gene Therapy Company Updates – September 20, 2023

Ocugen’s Gene-Agnostic Gene Therapy OCU400 Demonstrates Improvement or Stabilization in Retinitis Pigmentosa, Leber Congenital Amaurosis

First Patient Dosed With LCA5 Gene Therapy

Around the Helix: Cell and Gene Therapy Company Updates – September 27, 2023

Related Content

Patients Receiving Autologous Stem Cell Transplant After Chemical Burns Show Corneal Improvements

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

Optic Atrophy Gene Therapy Cleared for Trials in Australia

The phase 1/2 trial is opening its second phase of recruitment after being well-tolerated in the first 4 patients and demonstrating some vision improvements.

Around the Helix: Cell and Gene Therapy Company Updates – September 20, 2023

NFS-05 is an ophthalmic injection that uses an AAV vector to deliver the OPA1 gene to retinal ganglion cells.

Ocugen’s Gene-Agnostic Gene Therapy OCU400 Demonstrates Improvement or Stabilization in Retinitis Pigmentosa, Leber Congenital Amaurosis

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

First Patient Dosed With LCA5 Gene Therapy

Among 12 patients evaluable for efficacy, 10 patients experienced stabilization or improvement from baseline in BCVA in their treated eyes.